Fundraising Fox
Abcuro
Newton, US · Delaware corporation · 16 known investors
Find your way into Abcuro
618 people in our graph share verified history with the Abcuro team — schools, employers, funds. One of them is your warm intro.
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.
Founders & leadership
Board
Investors · 16
How we know: the company's own site · Bain Capital Life Sciences's portfolio page · press coverage · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: RA Capital's portfolio page · the company's own site · press coverage · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the company's own site · board seat on SEC Form D · press coverage · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · press coverage · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · press coverage · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · funding news · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$331.3M disclosed across 7 rounds · 2016–2026
- $66MSeries DAug 2026Source ↗
▶$39.4MraisedAug 2026 · 23 investors · BiotechnologyRule 506(b)
- John Alexander MartinExecutive Officer, Director
- Mark PruzanskiDirector
- Ron HuntDirector
- Michael DybbsDirector
- Ming FangDirector
- Sarah BoyceDirector
- Offering amount
- $176.5M
- Amount sold
- $39.4M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$80MraisedFeb 2025 · 21 investors · BiotechnologyRule 506(b)
- John Alexander MartinExecutive Officer, Director
- Sarah BoyceDirector
- Michele ParkDirector
- Mark PruzanskiDirector
- Jason HaflerDirector
- Rajeev ShahDirector
- Ming FangDirector
- Michael DybbsDirector
- Offering amount
- $200M
- Amount sold
- $80M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120.1MraisedAug 2023 · 21 investors · BiotechnologyRule 506(b)
- Julius KnowlesDirector
- Donald McCarthyDirector
- Rajeev ShahDirector
- John Alexander MartinExecutive Officer, Director
- Tomer KarivDirector
- Jason HaflerDirector
- Richard MotschwillerExecutive Officer
- Darlene Deptula-HicksDirector
- Offering amount
- $199.5M
- Amount sold
- $120.1M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.5MraisedJan 2021 · 15 investors · BiotechnologyRule 506(b)
- Stefano GullaExecutive Officer
- Jason HaflerDirector
- Ryan BerryDirector
- Donald McCarthyDirector
- John EdwardsDirector
- Yajun XuDirector
- Julius KnowlesDirector
- Evan ThompsonExecutive Officer
- David de GraafExecutive Officer, Director
- Iyona RajkomarDirector
- Offering amount
- $42M
- Amount sold
- $15.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedNov 2018 · 3 investors · BiotechnologyRule 506(b)
- K. Evan ThompsonExecutive Officer, Director
- Robert MillmanDirector
- Yajun XuDirector
- Stefano GullaExecutive Officer, Director
- Julius KnowlesDirector
- Nalan UtkuDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Proceeds to insiders
- $880K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2.3MraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
- Yajun XuDirector
- Julius KnowlesDirector
- Stefano GullaExecutive Officer, Director
- K. Evan ThompsonExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Proceeds to insiders
- $500K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Abcuro.
In the news
Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositisfinance.yahoo.com · Aug 2026
Abcuro Announces $66 Million Series D Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Abcuro do?
- Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis. The company is a clinical-stage biopharmaceutical firm running Phase 2/3 trials of its immunology treatments.
- Who founded Abcuro?
- Abcuro was founded by Steven A. Greenberg, Steven A. Greenberg, MD.
- Who are Abcuro's investors?
- Abcuro's investors include Bain Capital Life Sciences, New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, Sanofi Ventures, Mass General Brigham Ventures, REDMILE, Pontifax Venture Capital and 8 more.
- How much funding has Abcuro raised?
- Abcuro has disclosed $331.3M raised across 7 rounds.
- Where is Abcuro headquartered?
- Abcuro is headquartered in Newton, US.